Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiac, Neuropsychiatric Events With ADHD Drugs To Be Discussed By Pediatric Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Pediatric Advisory Committee will address neuropsychiatric and cardiovascular events possibly related to attention deficit/hyperactivity disorder medications at a March 22 meeting

You may also be interested in...



ADHD Individual Drug Risk Studies To Be Considered By Drug Safety Committee

FDA to present analysis of sudden death and serious cardiovascular event rates with amphetamine and methylphenidate products at Feb. 9 meeting of Drug Safety & Risk Management Advisory Committee.

ADHD Individual Drug Risk Studies To Be Considered By Drug Safety Committee

FDA to present analysis of sudden death and serious cardiovascular event rates with amphetamine and methylphenidate products at Feb. 9 meeting of Drug Safety & Risk Management Advisory Committee.

Cephalon Sparlon For ADHD To Get Psychopharm Committee Review

The March 23 review of the new indication for modafinil, currently marketed as Provigil for narcolepsy, will likely focus on safety differences compared to other ADHD drugs.

Related Content

Topics

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel